After over three years of intense negotiations, countries have reached a landmark agreement at the World Health Organization (WHO) headquarters to enhance global preparedness for future pandemics. The accord aims to rectify the shortcomings exposed during the COVID-19 crisis and to establish a more equitable and efficient global health framework.
The final agreement was adopted early Wednesday morning following a marathon session that concluded around 2:00 am local time. WHO Director-General Tedros Adhanom Ghebreyesus hailed the development as a significant milestone, stating, “Tonight marks a significant milestone in our shared journey towards a safer world.”
The core component of the agreement is the establishment of a Pathogen Access and Benefit-Sharing System (PABS). This system is designed to facilitate the rapid sharing of pathogen data with pharmaceutical companies, enabling swift development of diagnostic tools, treatments, and vaccines in response to emerging health threats.
A key point of contention during the negotiations was Article 11, which addresses the transfer of technology for pandemic health products to developing nations. During the COVID-19 pandemic, many low-income countries accused wealthier nations of hoarding vaccines and medical supplies. To address these concerns, the agreement stipulates that any technology transfer must be “mutually agreed,” balancing the needs of developing countries with the interests of pharmaceutical companies.
The agreement has been fully approved by all WHO member states, with negotiations co-chair Anne-Claire Amprou declaring, “It’s adopted,” to resounding applause. The finalized text will be presented for formal approval at the upcoming WHO annual assembly next month.
Global reactions to the agreement have been largely positive. European Union chief Ursula von der Leyen described it as “Excellent news from Geneva,” emphasizing the importance of solidarity and global cooperation in combating pandemics. She noted, “We have learnt the lessons of COVID. To beat a pandemic, you need tests, treatments and vaccines. And you equally need solidarity and global cooperation.”
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) also welcomed the agreement, highlighting the need for intellectual property protections and legal certainty to encourage investment in high-risk research and development. IFPMA chief David Reddy stated, “The pandemic agreement is a starting point.”
Developing countries and non-governmental organizations have expressed cautious optimism. A representative from Tanzania, speaking on behalf of numerous African nations, acknowledged that while the agreement may not have fully met all their aspirations, it has opened an important avenue for future collaboration.
As the negotiations concluded, WHO Director-General Tedros emphasized the urgency of the agreement, stating, “Virus is the worst enemy. (It) could be worse than a war.” He also noted that while measures to combat pandemics could be costly, “the cost of inaction is much bigger.”
The United States, which has significantly reduced its foreign aid spending and withdrawn from the WHO under President Donald Trump’s administration, was notably absent from the negotiations. The U.S. had previously threatened to impose tariffs on pharmaceutical products, adding complexity to the discussions.
Despite these challenges, the successful conclusion of the agreement is seen as a triumph for global cooperation and a critical step toward a more resilient global health system.
*
Email *
Website
